Sunder Biomedical Tech Co

Sunder Biomedical Tech Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Sunder Biomedical Tech Co (4115.TWO) as of Oct 28, 2026 is -7.62. In the previous year, Total Debt to EBITDA Ratio was 16.67 — a change of -145.72% (lower).

Debt/EBITDA

-7.62

YoY

-145.72%

Last updated:

Total Debt to EBITDA Ratio of Sunder Biomedical Tech Co is 2025 -7.62 . Total Debt to EBITDA Ratio of Sunder Biomedical Tech Co was 2024 16.67 . It decreases by -145.72% lower compared to the previous year.

The Sunder Biomedical Tech Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
11.66 TWD
Jan 1, 2020
9.60 TWD
Jan 1, 2021
6.51 TWD
Jan 1, 2022
30.16 TWD
Jan 1, 2023
-13.13 TWD
Jan 1, 2024
16.67 TWD
Jan 1, 2025
-7.62 TWD
The Sunder Biomedical Tech Co Debt/EBITDA history
YEARDebt/EBITDAYoY
-7.62-145.72%
16.67-226.91%
-13.13-143.54%
30.16+363.11%
6.51-32.18%
9.60-17.67%
11.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunder Biomedical Tech Co Stock analysis

What does Sunder Biomedical Tech Co do? Sunder Biomedical Tech Co Ltd manufactures and sells medical consumables including blood circuit catheters, puncture needles, infusion sets, suction tubing, dosing sets, waste fluid collection bags, and protective covers. The company also produces laparoscopic smoke filters, suction sets, pick-up bags, and medical grade materials such as PVC pellets, NON-diethylhexyl phthalate (DEHP) PVC, and other medical components. Additionally, Sunder Biomedical offers sterilization and laboratory services, along with foundry services for masks, tubes, and nucleic acid extraction well tray consumables. The primary buyers of Sunder Biomedical's products are healthcare facilities, hospitals, and medical institutions requiring disposable medical equipment and supplies. These clients purchase medical consumables for routine procedures, surgical operations, and patient care. The company's focus on medical grade materials ensures compliance with healthcare standards, making its products essential for medical professionals. Sunder Biomedical's revenue streams include direct sales of medical consumables, sterilization services, and foundry services for specialized medical components. The company targets the healthcare sector, particularly hospitals and clinics, where demand for reliable, high-quality disposable medical products is consistent. By providing a comprehensive range of medical supplies, Sunder Biomedical caters to the operational needs of healthcare providers across various medical specialties. Sunder Biomedical Tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunder Biomedical Tech Co stock

Total Debt to EBITDA Ratio of Sunder Biomedical Tech Co is -7.62 in 2025.

Total Debt to EBITDA Ratio of Sunder Biomedical Tech Co changed from 16.67 to -7.62, representing a -145.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Sunder Biomedical Tech Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Sunder Biomedical Tech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Sunder Biomedical Tech Co

All Key Metrics — Sunder Biomedical Tech Co